Aptevo Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de Aptevo Therapeutics' es Marvin White , nombrado en Aug 2016, tiene una permanencia de 7.67 años. compensación anual total es $873.45K, compuesta por 64.7% salario y 35.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.1% de las acciones de la empresa, por valor de $1.13K. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 7.7 años, respectivamente.

Información clave

Marvin White

Chief Executive Officer (CEO)

US$873.4k

Compensación total

Porcentaje del salario del CEO	64.7%
Permanencia del CEO	7.8yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2.3yrs
Promedio de permanencia en la Junta Directiva	7.8yrs

Actualizaciones recientes de la dirección

Recent updates

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Sep 19

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Nov 05

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Marvin White en comparación con los beneficios de Aptevo Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$873k	US$565k	-US$19m
Sep 30 2023	n/a	n/a	-US$18m
Jun 30 2023	n/a	n/a	-US$19m
Mar 31 2023	n/a	n/a	US$17m
Dec 31 2022	US$1m	US$565k	US$7m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$6m
Mar 31 2022	n/a	n/a	-US$30m
Dec 31 2021	US$3m	US$565k	-US$29m
Sep 30 2021	n/a	n/a	-US$30m
Jun 30 2021	n/a	n/a	-US$30m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$971k	US$498k	-US$31m
Sep 30 2020	n/a	n/a	-US$33m
Jun 30 2020	n/a	n/a	-US$37m
Mar 31 2020	n/a	n/a	-US$41m
Dec 31 2019	US$974k	US$547k	-US$43m
Sep 30 2019	n/a	n/a	-US$48m
Jun 30 2019	n/a	n/a	-US$49m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$1m	US$565k	-US$54m
Sep 30 2018	n/a	n/a	-US$49m
Jun 30 2018	n/a	n/a	-US$34m
Mar 31 2018	n/a	n/a	-US$35m
Dec 31 2017	US$1m	US$543k	-US$33m

Compensación vs. Mercado: La compensación total de Marvin($USD873.45K) está por encima de la media de empresas de tamaño similar en el mercado US ($USD663.90K).

Compensación vs. Ingresos: La compensación de Marvin ha sido consistente con los resultados de la empresa en el último año.

CEO

Marvin White (61 yo)

7.8yrs

Permanencia

US$873,446

Compensación

Mr. Marvin L. White has been Independent Director at Emergent BioSolutions Inc. since 2022 and served as its Director since October 1, 2020 until 2022. Mr. White has been the Chief Executive Officer, Presi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Marvin White	President	7.8yrs	US$873.45k	0.095% $ 1.7k
Jeffrey Lamothe	Executive VP & COO	1.2yrs	US$741.59k	0.053% $ 945.7
SoYoung Kwon	Senior VP	2.8yrs	US$654.73k	0.034% $ 606.1
Daphne Taylor	Senior VP & CFO	1.2yrs	sin datos	0.026% $ 463.9
Dirk Huebner	Chief Medical Officer	2.3yrs	sin datos	sin datos

2.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de APVO se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Marvin White	President	7.8yrs	US$873.45k	0.095% $ 1.7k
Daniel Abdun-Nabi	Independent Director	7.8yrs	US$73.21k	0.012% $ 210.8
Zsolt Harsanyi	Independent Director	7.8yrs	US$93.21k	0.012% $ 214.2
John Niederhuber	Independent Chairman	7.8yrs	US$88.21k	0.0080% $ 143.2
Barbara Kunz	Independent Director	7.8yrs	US$78.21k	0.0069% $ 123.2
Grady Grant	Independent Director	7.8yrs	US$70.71k	0.0069% $ 123.2

7.8yrs

Permanencia media

67.5yo

Promedio de edad

Junta con experiencia: La junta directiva de APVO se considera experimentada (7.7 años de antigüedad promedio).

Aptevo Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Insufficient new directors

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Insufficient new directors

Insufficient new directors

Recent updates

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Price target increased by 49% to US$671

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

New major risk - Share price stability

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Price target decreased by 33% to US$12.00

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings: EPS exceeds analyst expectations

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Consensus forecasts updated

Price target decreased to US$18.00

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Aptevo Therapeutics receives approval to begin human trial of solid tumor therapy

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Consensus revenue estimates fall by 15%

Price target decreased to US$52.50

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Price target decreased to US$59.50

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo meets primary endpoint in early-stage trial for blood cancer therapy

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Aptevo: Positive Early Stage Data Makes This Highly Interesting

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo gets $50/share takeout offer from shareholder Tang

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Aptevo Therapeutics rallies 113% as Tang Capital discloses 54% stake

Aptevo sells off after clarifying complete response in early-stage study on lead drug

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad